Medical News
Myasthenia Gravis and Unmet Patient Needs – Data from Clinical Practice
Myasthenia gravis (MG) is a rare, chronic, disabling, unpredictable, and potentially life-threatening autoimmune neuromuscular disease. There is still a lack of sufficient data from real clinical practice to better meet the needs of MG patients. What is the current situation in European countries? And how are Czech patients doing?
Side Effects of Antipsychotics and Patient Preferences in the Treatment of Schizophrenia
Although a number of antipsychotics are currently available, many patients still suffer from unpleasant side effects associated with the treatment of schizophrenia. To determine how individuals with…
Physical Activity in Young Men with Hemophilia A
What may influence the inclusion of physical activity in the lifestyle of individuals with hemophilia? This was the focus of a Norwegian study published in the journal Haemophilia.
N9-GP in Previously Treated Pediatric Patients with Hemophilia B – Extended Follow-up
An analysis of extended treatment with nonacog alfa pegol (N9-GP) in pediatric patients with hemophilia B evaluated the long-term safety and effectiveness of this prophylactic modality.
Pain Management in Patients After Hip and Knee Arthroplasty – Data from Clinical Practice
Inadequate analgesia after hip and knee arthroplasty can result in delayed postoperative recovery accompanied by chronic pain. The retrospective study presented below compared the efficacy of…
Subcutaneous Immunoglobulin Therapy in Patients with Secondary Immunodeficiency – Real-World Data
Even in patients with secondary immunodeficiency (SID), immunoglobulin substitution can be indicated. Intravenous (IVIG) therapy is considered effective based on studies, but subcutaneous (SCIG) therapy...
Romiplostim in ITP Treatment – Data from German Clinical Practice
Real-world clinical practice data from Germany confirm the beneficial effect and safety profile of romiplostim in patients with immune thrombocytopenia (ITP), both newly diagnosed, persistent, and…
Invasive Pneumococcal Disease – Current Czech Data
The number of reported cases of invasive pneumococcal disease (IPD) returned to levels comparable to those before the COVID-19 pandemic in 2022. Regarding age-specific morbidity, the most at-risk…
Do Gliflozins Affect the Need to Use Diuretics?
Sodium-glucose cotransporter 2 inhibitors (SGLT2i, i.e., gliflozins) have advanced from their initial role in reducing hyperglycemia in the treatment of type 2 diabetes mellitus (DM2) to…
Rapid Strengthening and Long-term Stabilization – New Strategy for Sequential Treatment of Severe Osteoporosis
Osteoanabolics have long been considered a treatment modality for osteoporosis that is only considered when antiresorptive medication lacks the desired efficacy. However, their role has been shifting…
Inhibition of Sclerostin in Osteoporosis Therapy
Romosozumab, a subcutaneously administered antibody against sclerostin, is one of the most potent osteoanabolics and appears to be a highly effective modality in the treatment of postmenopausal…
Doc. Tomáš Gabrhelík: Pain treatment should be seriously addressed by all fields, especially in seniors
Chronic pain is often underestimated, especially in older and polymorbid patients. On the other hand, during self-treatment, many patients use inappropriate medication for a long time. The treatment…
Ocrelizumab in the treatment of multiple sclerosis in real-world practice – a systematic review of published studies
In controlled study programs, ocrelizumab has demonstrated beneficial effects on improving clinical parameters in patients with multiple sclerosis, such as the annual relapse rate or confirmed…
Innovation in Wound Healing: Zetuvit Plus Silicone Border for Optimal Wound Exudate Management
Excessive wound exudate can lead to delayed healing, skin damage around the wound, or leakage under the chosen dressing. Zetuvit Plus Silicone Border dressing with high absorbent and retention…
Current Data of Tofacitinib in the Treatment of IBD: What Improvements in Endoscopic and Histologic Outcomes Can Be Achieved?
The oral Janus kinase inhibitor (JAKi) tofacitinib is currently approved for the treatment of moderately to severely active ulcerative colitis (UC). Its efficacy and safety in this indication have…